DALLAS, May 5, 2020 -- A new genetic risk score based on 29 mutations in the blood identified more men at increased risk for an abdominal aortic aneurysm and who could benefit from screening to detect it prior to rupture, according to preliminary research presented at the American Heart Association's Vascular Discovery: From Genes to Medicine Scientific Sessions 2020. The meeting is a virtual event in 2020, to be held May 5-7, and is a premier global exchange of the latest advances in new and emerging scientific research in arteriosclerosis, thrombosis, vascular biology, peripheral vascular disease, vascular surgery and functional genomics.
"I think this is the future of precision medicine - to use someone's genetics to identify those at high risk and to screen and potentially treat them before it becomes a problem," said Derek Klarin, M.D., lead author of the study and a vascular surgery fellow at the University of Florida College of Medicine in Gainesville, Florida.
Abdominal aortic aneurysm occurs when there is enlargement or a weakening of the wall of the large blood vessel that supplies blood to the abdomen and lower body. The condition is found most often in men over the age of 60 who have a family history of aneurysm, have been smokers or have other heart disease risk factors. If the aneurysm weakens the vessel wall to the point that it ruptures, it is a life-threatening medical emergency with a survival rate of about 20%.
In order to detect more abdominal aortic aneurysms before it is an emergency, in December 2019, the United States Preventive Services Task Force (USPSTF) announced updated recommendations for a one-time ultrasound screening of men between 65 and 75 years of age who have ever smoked. If an aneurysm is detected, it can be monitored to determine if it is small, can be surgically repaired and allow for treatment if it grows large enough to raise concerns about rupture (more than 5.5 cm or 2-1/6 inches).
"We focused on whether we could use a series of genetic mutations to develop a score that could stratify who is at higher risk of developing an abdominal aortic aneurysm," Klarin said.
Researchers identified genetic variants that raise the risk of abdominal aortic aneurysm by comparing more than 7,600 veterans with abdominal aortic aneurysm and more than 172,000 without the condition who were genotyped as part of the Million Veteran Program of the U.S. Department of Veteran Affairs.
"We identified 29 genetic mutations related to abdominal aortic aneurysm risk that are relatively common in the population and created a polygenic risk score - basically a way to add them all up to quantify how much risk you have based on your genetics," said Klarin.
In the study, among veterans 50 years of age and older who scored in the top 5% of genetic risk, 7.8% had been diagnosed with abdominal aortic aneurysm.
"This is a slightly higher risk than the 6-7% occurrence in men 65 and over who would be screened under the USPSTF's recommendations," Klarin said.
"Currently, this type of screening is not available from your doctor. Our results suggest current screening recommendations should be extended to include testing for those with high polygenic risk scores to allow for early intervention and prevention of abdominal aortic aneurysm," Klarin said.
Although the study involved only veterans, the researchers obtained the same results when they repeated the analysis in a sample of Mayo Clinic patients and participants from two other biobanks. Because the database included primarily white men, the results may not be applicable to women and men from other ethnic groups.
"We still need to do more work in understanding how best to identify women who will develop an abdominal aortic aneurysm. We have some data on African-American veterans, who in general are at lower risk; however, the genetics of the disease are not the same, so more data are needed," Klarin concluded.
Co-authors are Shefali S. Verma, Ph.D.; Ozan Dikilitas, M.D.; Brooke Wolford, B.S.; Michael Levin, M.D.; Ishan Paranjpe, B.S.; Renae Judy, M.S.; Julie Lynch, Ph.D., R.N.; Themistocles L. Assimes, M.D., Ph.D.; Yan V. Sun, Ph.D.; Daniel J. Rader, M.D.; Peter W. Wilson, M.D.; Salvatore T. Scali, M.D.; Scott A. Berceli, M.D., Ph.D.; Sekar Kathiresan, M.D.; Pradeep Natarajan, M.D., M.M.Sc.; Girish Nadkarni, M.D., M.P.H..; Cristen Willer, Ph.D.; Iftikhar Kullo, M.D.; Scott M. Damrauer, M.D.; and Philip S. Tsao, Ph.D. Author disclosures are in the abstract.
Note: The study will be presented at 3:25 p.m. CT, May 6, 2020; the virtual meeting link is available here.
Researcher photo available on the right column of the release link https:/
Follow news from the American Heart Association's Vascular Discovery Scientific Sessions 2020 via Twitter: @HeartNews #VascularDiscovery20
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https:/
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public's health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.